Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CETP | P11597 | 11/20 | 0.40 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | LIPC | P11150 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27634301 | 1.00 | MAPT (0.40) | MAPTCETPAADATALDH1A1SMN1; SMN2 | |
| SCHEMBL27633727 | 1.00 | MAPT (0.40) | MAPTCETPAADATALDH1A1SMN1; SMN2 | |
| SCHEMBL5777131 | 0.87 | CETP (0.53) | CETP | |
| SCHEMBL5773078 | 0.87 | CETP (0.53) | CETP | |
| SCHEMBL31193445 | 0.87 | CETP (0.53) | CETP | |
| SCHEMBL5777809 | 0.87 | CETP (0.48) | MAPTCETPALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL31193476 | 0.87 | CETP (0.53) | CETP | |
| SCHEMBL5776774 | 0.87 | CETP (0.53) | CETP | |
| SCHEMBL5778438 | 0.86 | CETP (0.43) | MAPTCETP | |
| SCHEMBL27634352 | 0.85 | MAPT (0.38) | MAPTCETPAADATALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1795177-A | 1, 2, 4-substituted 1, 2, 3, 4-tetrahydro-and 1, 2 dihydro-quinolines and 1, 2, 3, 4-tetrahydro-quinoxaline derivatives as CETP inhibitors for the treatment of atherosclerosis and obesity | PFIZER PROD INC (US) | 2006-06-28 | — | — | CN | disclosed |